Navigation Links
E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis

E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi-... -- PARIS, Nov. 1, 2010 /PRNewswire-Asia/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Banking & Financial Services, Biotechnology, Health Care & Hospitals, Medical Pharmaceuticals, Pharmaceuticals, Acquisitions, Mergers and Takeovers Click to view news release full screen  

E. J. McKay Advises BMP Sunstone on Its USD520.6 million Sale to Sanofi- aventis


PARIS, Nov. 1, 2010 /PRNewswire-Asia/ -- Sanofi-aventis (EURONEXT: SAN; NYSE: SNY) and BMP Sunstone Corporation (Nasdaq: BJGP) announced today that they have signed a definitive agreement under which Sanofi-aventis is to acquire all outstanding shares of BMP Sunstone for USD10 per share, for a total purchase price of USD520.6 million on a fully diluted basis. This price per share represents a 30% premium on BMP's October 27, 2010 closing share price. E. J. McKay and Stephens Inc. acted as BMP Sunstone's financial advisors, while Morgan Stanley represented Sanofi-aventis.

The acquisition of BMP Sunstone, which holds many leading Chinese pediatric and hygienic brands, will provide Sanofi-aventis with significant growth opportunities in the Chinese healthcare market, and specifically in its two largest categories: Vitamin & Minerals Supplements and Cough & Cold.

This transaction marks the largest Chinese pharmaceutical deal of the year, and is a prime example of the synergies and value that cross-border transactions can create. E. J. McKay CEO James Z. Li stated, "We are very pleased with the positive outcome. This acquisition will significantly boost Sanofi-aventis' China presence, meanwhile creating significant value for BMP Sunstone's shareholders. It is representative of the selectivity of our clients and the value and expertise E. J. McKay provides."

About sanofi-aventis

Sanofi-aventis, a leading global pharmaceutical company, discovers, develops and distributes therapeutic solutions to improve the lives of everyone. Reporting revenue of EUR29.3 billion in 2009, the company maintains over 100,000 employees in over 100 countries.

About BMP Sunstone

BMP Sunstone Corporation is a specialty pharmaceutical company that is building a proprietary portfolio of branded pharmaceutical and healthcare products in China. Through Sunstone, the Company manufactures leading pediatric and women's health products sold in pharmacies throughout the country. The Company also markets a portfolio of products under exclusive multi-year licenses into China, as well as provides pharmaceutical distribution.

About E. J. McKay

E. J. McKay is a Shanghai based investment banking group specialized in structuring complex cross-border mergers & acquisitions and merchant banking transactions. Through its offices and strategic partnerships, the firm is present in thirty major financial centers around the world. E. J. McKay has a dedicated focus on China, and advises transactions both inbound and outbound, representing clients both local and multinational.

Contact: Natalie Hsiao Tel: +86-21-5109-6266 Email:

Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Intermountain McKay-Dee Hospital Center Expands Real-Time Locating Solution From Versus Technology, Inc.
2. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
3. Glass Lewis Advises Taro Shareholders to Hold Taros Board Accountable for Its Failures
4. BMP Sunstone Announces the Inclusion of Seventy Eight Drugs in Chinas National Insurance Catalog
5. BMP Sunstones Hao Wawa (Good Baby) Brand Ranked First Among Chinas Top Three Pediatric Medicine Brands
6. Sanofi-aventis to Acquire BMP Sunstone Creating a Strong Consumer Healthcare Platform in China
7. Globus Medical Raises $110 Million in Series E Financing Round
8. Atritech Announces Completion of a $22 Million Equity Financing
9. The Female Health Company Receives USAID DELIVER PROJECT Order for 5 Million Units
10. EntreMed Raises $20 Million to Support Clinical Development Program
11. Niaid / Barda Awards Elusys a $12 Million Contract to Further Develop Anthim, the Companys Anthrax Therapeutic
Post Your Comments:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):